

PRESS RELEASE

Publication of Kvac cancer vaccine paper shows safety and efficacy in animals

Sydney, Australia – 6 March 2014

Regenerative medicine company Regeneus (ASX: RGS), announced today that a paper describing safety and early efficacy data for the Kvac cancer vaccine has been published in *Cancer Immunology Research*, the peer-reviewed journal published by the American Association for Cancer Research. This journal targets groundbreaking original articles on major advances in cancer immunology.

The Kvac vaccine uses the removal of a tumour or biopsy from the patient as source material to produce a personalised vaccine. The vaccine stimulates the patient's immune system to see the cancer cells as foreign and helps prevent further growth of the tumour as well as development of new tumours.

The technology was developed by Professor Ross Davey and Dr Chris Weir at the Bill Walsh Translational Cancer Research Laboratory, which is part of the Kolling Institute of Medical Research at the Royal North Shore Hospital in Sydney. Regeneus has an exclusive worldwide licence for commercialisation of the technology for veterinary applications and an option over all human applications.

The paper describes experimental work in a pre-clinical rat glioma (brain tumour) model and showed that the vaccine led to remission rates of 30%-60%. Furthermore upon re-challenge these animals did not get the disease, which indicates acquired immunity. The paper also described the treatment of 25 dogs that had a range of advanced cancers. These companion animals presented at veterinary clinics in Sydney with cancer types ranging from melanoma to bone cancer. Dr Chris Weir produced personalised vaccines for the vets to administer to the dogs. The study in dogs demonstrated that there were no safety issues with the vaccine and that the dogs often survived longer than expected indicating that the vaccine can slow tumor growth and recurrence.

"The results from the work in rats is a major breakthrough," said Dr Chris Weir from Bill Walsh Translational Cancer Research Laboratory. "The 9L glioma model is extremely aggressive, and achieving the level of remission and immunity that we did, using a vaccine derived from tumours is significant and unique".

"This is very exciting," says Duncan Thomson – Head of the Veterinary Business Unit for Regeneus. "The work in dogs suggests that the vaccine is effective in a wide range of tumour types, which makes this a very significant commercial opportunity".

This follows the company's announcement in November 2013 that Regeneus received the green light to commercialise the canine vaccine in the United States through the Centre for Veterinary Biologics at the US Department of Agriculture.

The next steps for Regeneus involves setting up a vaccine manufacturing site in the US and beginning a marketing trial with key opinion leaders in the US.

According to the US National Canine Cancer Foundation, cancer accounts for almost half of the deaths of pets over 10 years of age, which is roughly the same rate as humans.

The paper can be accessed at:

"Streptavidin: A novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines" (<http://cancerimmunolres.aacrjournals.org/content/early/by/section>).

END

Contacts and further information:**Investors:**

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au

Media:

Clare Serafini
Communications Manager, Regeneus Ltd
T: +61 2 9499 8010
Mobile: 0417 299 081
E: clare.serafini@regeneus.com.au or go to www.regeneus.com.au

About Regeneus:

Regeneus Ltd (ASX: RGS) is a Sydney based ASX listed regenerative medicine company. It develops and commercialises novel technologies for the preparation of autologous (using a patient's own cells) and allogeneic (using donor cells) cell therapies using adipose (fat)-derived regenerative cells including mesenchymal stem cells for the treatment of musculoskeletal and other inflammatory conditions in humans and animals.

About Bill Walsh Translational Cancer Research Laboratory:

Located on the grounds of Royal North Shore Hospital in Sydney, the Bill Walsh Translational Cancer Research Laboratory is part of the Kolling Institute of Medical Research which is affiliated with The University of Sydney's Sydney Medical School – Northern and is the principal centre of health and medical research for the Northern Sydney Local Health District.

The Bill Walsh Translational Cancer Research Laboratory is the research arm of the Medical Oncology Department at Royal North Shore Hospital. The Laboratory's research activities are strongly focused on improving cancer treatment, undertaking preclinical studies that can then be fast-tracked into clinical practice.

<http://www.bwcancerresearchlab.org.au>

About Cancer Immunology Research:

Cancer Immunology Research is an international peer-reviewed journal. It publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. The journal will disseminate knowledge of immunology to the cancer research community, catalyzing cross-disciplinary work that yields a deeper understanding of the host-tumor relationship, more potent cancer treatments, and improved clinical outcomes.

About the American Association for Cancer Research:

Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate

progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees.

In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.